Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 9 June 2022, 1.00 p.m. (Brussels time) RECOMMENDED ACQUISITION of ACACIA PHARMA GROUP PLC by EAGLE PHARMACEUTICALS, INC. to be effected by means of a scheme of arrangement under...
Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AND REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 7 June 2022, [1.00] p.m. (Brussels time) RECOMMENDED ACQUISITION of ACACIA PHARMA GROUP PLC by EAGLE PHARMACEUTICALS, INC. to be effected by means of a...
Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AND REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 20 May 2022, 8:00 a.m. (Brussels time) RECOMMENDED ACQUISITION of ACACIA PHARMA GROUP PLC by EAGLE PHARMACEUTICALS, INC. to be effected by means of a scheme...
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 29 April 2022, 23:00 CEST : Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive...
Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 27 April 2022, 12:00 p.m. (Brussels time) RECOMMENDED ACQUISITION of ACACIA PHARMA GROUP PLC by EAGLE PHARMACEUTICALS, INC. to be effected by means of a scheme of arrangement under...
THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. Publication in application of Article 15 of the Law of 2 May 2007 (the Transparency Law) Cambridge, UK and Indianapolis, US – 31 March 2022, 18:00 CET . As previously announced 1 , Acacia Pharma Group plc issued ordinary shares to its Employee Benefit Trust within the authorised capital. The gross amount of this capital increase amounted to GBP 1,274,20 via an issue of 63,710 new shares at an issue price of GBP 0.02 per share. The shares were...
THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION Not for release, publication or distribution, in whole or in part, directly or indirectly in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction For immediate release 30 March 2022, 6 :00 p .m. (Brussels time) Cambridge, UK and Indianapolis, US – Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), announces that it will not publish its results for...
ACACIA PHARMA GROUP PLC PROPOSED TRANSACTION WITH EAGLE PHARMACEUTICALS, INC. THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION AND INSIDE INFORMATION Not for release, publication or distribution, in whole or in part, directly or indirectly in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction For immediate release 28 March 2022, 08:00 a.m. (Brussels time) RECOMMENDED SCHEME OF ARRANGEMENT of ACACIA PHARMA GROUP PLC by EAGLE...
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 23 March 2022: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or cancer chemotherapy,...
This announcement contains regulated information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 15 March 2022: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures...
THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. Publication in application of Article 15 of the Law of 2 May 2007 (the Transparency Law) Acacia Pharma Group plc As previously announced 1 , Acacia Pharma Group plc issued ordinary shares to its Employee Benefit Trust within the authorised capital. The gross amount of this capital increase amounted to GBP 22,909.44 via an issue of 1,145,472 new shares at an issue price of GBP 0.02 per share. The shares were issued to satisfy the vesting of share...
Correction – Admission Date for New Ordinary Shares Included This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 16 December 2021: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing...
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 16 December 2021: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures...
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 13 December 2021: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or cancer chemotherapy,...
Cambridge, UK and Indianapolis, US – 10 November 2021: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), is pleased to announce that its Chief Executive Officer, Mike Bolinder will present at the Jefferies London Healthcare Conference 2021 on Tuesday, 16 November 2021. The presentation will begin at 09:20 GMT / 10.20 CET and a live video webcast will be available to registered conference attendees. The link to the webcast is available here ....
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Acacia Pharma Group plc Barhemsys® and Byfavo® launches continue to show strong progress gaining formulary access in 107 additional accounts over the past 3 months For Barhemsys – 260 accounts on formulary with >80% win rate to date and well on track to meet annual formulary goal (300 accounts) by year end For Byfavo – 95 accounts on formulary with >90% win rate to...
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 29 September 2021: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or cancer...
Correction for date of KOL webcast Acacia Pharma to Report its Interim Results for the Six Months ended 30 June 2021 on 30 September 2021 Conference Call to be held on 30 September at 14.00 CEST/08.00 EST Cambridge, UK and Indianapolis, US – 23 September 2021, 13:00 CEST: Acacia Pharma Group plc (“Acacia Pharma” or the "Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients...
Acacia Pharma to Report its Interim Results for the Six Months ended 30 June 2021 on 30 September 2021 Conference Call to be held on 30 September at 14.00 CEST/08.00 EST Cambridge, UK and Indianapolis, US – 23 September 2021, 13:00 CEST: Acacia Pharma Group plc (“Acacia Pharma” or the "Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such...
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 16 September 20 2 1 : 07:00 CET Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other...
